glp3.wiki
Investigational · not FDA approved

Editorially reviewed · Last updated September 8, 2026 · How we review

Nick Trigili on Retatrutide: His 10-Week Protocol vs What the Data Shows

Part of YouTube & Expert Fact Checks.

Nick Trigili on Retatrutide: His 10-Week Protocol vs What the Data Shows

On January 22, 2026, Nick Trigili, whose channel describes him as a human performance specialist, published a video titled "Retatrutide is Changing Fat-Loss in 2026 (Beginners Guide)" documenting his personal 10-week retatrutide experiment. Trigili — who describes himself as someone who "spent years abusing fat burners, stimulants, and steroids" — broke down the TRIUMPH-4 Phase 3 trial data, walked through his dosing and peptide stacking protocol, and shared his results.
This review checks the retrieved transcript against trial reports. His account is self-reported and does not verify the identity of the product, his laboratory results or the degree of medical supervision. The video description claims physician oversight for clients; that is not independent evidence about his own experiment. Retatrutide remains investigational.

The TRIUMPH-4 Data: What He Got Right

Trigili walked through the TRIUMPH-4 Phase 3 trial results with reasonable accuracy on the headline numbers:

"The Triumph 4 was a 68-week study with 445 participants... At 12 milligrams, the average weight loss was nearly 28.7%. That's over 70 lbs on average. The 9 milligram group wasn't far behind that. It was 26.4%."

— Nick Trigili

The sequence he describes matches the TRIUMPH-4 release: all participants started at 2 mg, then escalated every four weeks toward their assigned dose. Phase 2 included both 2 mg and 4 mg starts in some groups, but the separate trials do not isolate how much any change in tolerability came from escalation.

ClaimPublished DataVerdict
68-week study, 445 participants with OAConfirmed by Eli Lilly press release (Dec 2025)Accurate
12mg group: 28.7% weight loss (~71 lbs)28.7% / 71.2 lbs (efficacy estimand)Accurate
9mg group: 26.4% weight loss26.4% / 64.2 lbs (efficacy estimand)Accurate
Titration: 2 → 4 → 6 → 9 → 12 every 4 weeksConfirmed by Lilly press releaseAccurate
Phase 2 had faster dose escalationPhase 2 used 4mg starting doses in some groupsPartially accurate
The 28.7% figure is the efficacy estimand, which estimates the effect assuming participants continued treatment; it is not simply the average among completers. The treatment-regimen estimate was 23.7% at 12 mg, versus 4.6% with placebo. Neither figure predicts an individual result or establishes superiority to drugs tested in other trials.
For the full trial data, see Retatrutide Results. For the mechanism, see What Is Retatrutide.

The Dropout Figure: Transcript and Trial Data

The retrieved transcript contains an internally inconsistent dropout passage:

"Even with a slower titration, almost 80% of people on the 12 milligrams still dropped out from the side effects. Nearly one in five couldn’t even tolerate the highest doses."

— Nick Trigili

The actual data from TRIUMPH-4 shows that 18.2% discontinued due to adverse events at the 12mg dose — not 80%. At 9mg, the rate was 12.2%, compared to 4.0% for placebo.
DoseDiscontinuation Due to AEsWhat Trigili Claimed
12 mg18.2%~80%
9 mg12.2%—
Placebo4.0%—

The adjacent “one in five” wording is consistent with the order of magnitude of 18.2%, while “80%” is not. Without resolving the original audio, this review cannot determine whether that was a spoken slip or transcription error. The source of the error is uncertain; the trial’s adverse-event discontinuation rate is not.

For the full safety data, see Retatrutide Side Effects.

Inflammation and Joint Pain: Mostly Accurate

Trigili highlighted the osteoarthritis results, claiming that knee pain "dropped over 76%" and that "pain reduction happened faster than weight loss":

"This trial was done on people with knee arthritis... And the pain that they were suffering with dropped over 76%. That's unheard of... the pain reduction happened faster than the weight loss. That tells us something else is going on here. Retatrutide is 100% reducing systemic inflammation."

— Nick Trigili

ClaimPublished DataVerdict
Knee pain dropped over 76%WOMAC pain: -75.8% (9mg), -74.3% (12mg)Approximately correct
Pain reduction faster than weight lossDetailed time-course data not yet publishedUnverifiable
Retatrutide reduces systemic inflammationhsCRP improved, but this does not prove a direct effect independent of weight lossBiomarker result; causal claim unproven
Improvements in HDL, triglycerides, CRP, BPNon-HDL cholesterol (not HDL), triglycerides, hsCRP, and systolic BP confirmedMostly accurate (HDL vs non-HDL distinction)

Lilly reported 75.8% pain reduction at 9 mg and 74.3% at 12 mg under the efficacy estimand. These values do not establish that retatrutide directly reduced systemic inflammation independently of weight loss. The cited report does not supply the analysis needed to establish his proposed timing-based mechanism.

For the full osteoarthritis data, see Retatrutide and Osteoarthritis.

His Personal Protocol

Trigili described a 10-week personal experiment using grey market retatrutide. He started at roughly 250–255 lbs at an estimated 12–15% body fat, with a goal of reaching single-digit body fat while preserving muscle:

His reported dosing (not a recommended regimen):
  • Weeks 1–2: 2mg weekly
  • Weeks 3–5: 4mg weekly
  • Weeks 6–8: 6mg weekly
  • Did not push to 9mg or 12mg
Training changes:
  • Reduced volume roughly 40%
  • Higher intensity, longer rest periods
  • Switched from stairmaster cardio to walking only
  • Rep range shifted to 12–15 (from 8–12)
Nutrition:
  • Protein: he gives a high-protein target, but the transcript does not clearly state the weight unit
  • Carbs: moderate, unchanged from baseline
  • Calories: approximately 2,000–2,500 per day
  • Priority order: protein first, then carbs, then fats
Results after 10 weeks:
  • Weight dropped from ~252 lbs to 218–225 lbs (25+ lbs lost)
  • Estimated body fat: 7–8% (self-assessed, not measured)
  • A1C dropped to under 5.0%
  • No significant strength loss
  • Reported elimination of joint pain from prior injuries
Important context: Trigili says he estimated body fat visually rather than measuring it. The product identity, laboratory results and degree of supervision were not independently verified. His reported starting condition, goals, training changes and concurrent substances differ from a controlled obesity trial, so his outcome cannot establish what retatrutide alone did.
For the regimens studied in trials and their limits, see Retatrutide Dosage. For why grey market sourcing carries risks, see Grey Market Retatrutide.

Peptide Stacking: No Clinical Evidence

Trigili described stacking retatrutide with several other peptides simultaneously:

"I stacked it with CJC-1295 and ipamorelin because I wanted to make sure my growth hormone stayed elevated and my sleep quality and my recovery stayed very good."

— Nick Trigili

His full stack included:

PeptideHis Stated PurposeClinical Evidence for Combination
CJC-1295 + IpamorelinGrowth hormone elevation, sleep qualityNo data on combining with retatrutide
BPC-157Joints, gut stability, inflammationFDA reviewed small human studies and older randomized abstracts; no established evidence for this combination
GHK-CuSkin elasticity, collagen supportNo data on combining with retatrutide

The studies reviewed here do not establish the safety or effectiveness of retatrutide with these substances. The FDA’s peptide reviews identify limited evidence and safety concerns; monitoring alone does not validate an unstudied combination.

This is a personal account with multiple simultaneous changes. It cannot identify which substance, training change or dietary change caused an effect.

For what clinical data shows about body composition, see Retatrutide and Muscle Loss.

Tapering Off: An Unvalidated Approach

Trigili described tapering off retatrutide gradually rather than stopping abruptly:

"I was not coming off cold. That'd be crazy and dumb. I tapered off everything slowly because I wanted to bring my calories back up slowly."

— Nick Trigili

His report does not establish that tapering retatrutide prevents hunger or weight regain, or that it is safer than another approach. The sources reviewed here do not validate his exit regimen. A favorable experience cannot substitute for a controlled discontinuation study.

Frequently Asked Questions

Who is Nick Trigili?

His channel describes him as a human performance specialist. The January 2026 video combines a trial discussion with a personal experiment and promotion of coaching. The review uses its retrieved transcript, not independently verified clinical records.

Was Nick Trigili accurate about the TRIUMPH-4 data?

The headline weight-loss percentages match Lilly’s efficacy-estimand results. The dropout transcript is inconsistent: it says “80%” and then about one in five. The actual 12 mg adverse-event discontinuation rate was 18.2%. The inflammation discussion also goes beyond what the biomarker findings establish.

Did Nick Trigili's protocol follow the clinical trial dosing?

Partially. He followed a modified version of the Phase 3 titration — starting at 2mg and escalating through 4mg and 6mg — but his schedule was compressed (2 weeks, then 3 weeks per step instead of 4 weeks). He also stopped at 6mg rather than continuing to 9mg or 12mg. The identity and potency of the product he used were not independently verified.

Is it safe to stack retatrutide with other peptides?

The reviewed studies do not establish the safety or effectiveness of the combinations described. Clinical monitoring does not by itself validate a combination, and the personal account cannot isolate retatrutide’s contribution.

Is Nick Trigili's experience typical of retatrutide results?

His self-reported body-fat estimates, concurrent substances and training changes do not provide a representative trial outcome. His experience cannot predict another person’s response or establish the effect of retatrutide alone.

Sources

  • FDA. (2026). BPC-157 briefing for the Pharmacy Compounding Advisory Committee. FDA briefing
  • FDA. Current concerns about unapproved GLP-1 drugs. FDA
  • Trigili, N. (2026). "Retatrutide is Changing Fat-Loss in 2026 (Beginners Guide)." YouTube. Watch on YouTube
  • Eli Lilly and Company. (2025). Lilly's retatrutide achieved significant weight loss and pain relief in adults with obesity and knee osteoarthritis. Press release
  • Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
  • Coskun, T., et al. (2025). Body composition substudy of retatrutide Phase 2 trial. The Lancet Diabetes & Endocrinology. DOI: 10.1016/S2213-8587(25)00092-0
How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Keep exploring

Explore all fact checks topics →